SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Li, Chenguang; Zhang, Jie; Xue, Mei; Li, Xiaoyu; Han, Fei; Liu, Xiangyang; Xu, Linxin; Lu, Yunhong; Cheng, Ying; Li, Ting; Yu, Xiaochen; Sun, Bei; Chen, Liming

doi:10.1186/s12933-019-0816-2

Public

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Published in Cardiovascular Diabetology • Feb 2, 2019

Authors:

Chenguang Li

Jie Zhang

Mei Xue

Abstract

BACKGROUND: Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-i...

Subject

Empagliflozin

Medicine

Angiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!